Cargando…

Diffuse Large B-Cell Lymphoma Treated With R-CHOP in a Resource-Limited Setting in South Africa: A Real-World Study

BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin’s lymphoma worldwide and particularly in Africa, where the incidence of HIV is the highest in the world. R-CHOP is the standard of care regimen for DLBCL, but access to rituximab is limited in developing coun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Musimar, Zola, Mpetani, Mtonga, Abramson, Jeremy S, Chabner, Bruce A, Mohamed, Zainab
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Hematologic Malignancies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485283/ https://www.ncbi.nlm.nih.gov/pubmed/37053476 http://dx.doi.org/10.1093/oncolo/oyad069

Ejemplares similares

Translating the Biology of Diffuse Large B-cell Lymphoma Into Treatment
por: Danilov, Alexey V, et al.
Publicado: (2022)

Clinical Treatment Guidelines for Tafasitamab plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Nedved, Adrienne, et al.
Publicado: (2023)

Validation and Refinement of the Age, Comorbidities, and Albumin Index in Elderly Patients with Diffuse Large B‐Cell Lymphoma: An Effective Tool for Comprehensive Geriatric Assessment
por: Liu, Hui, et al.
Publicado: (2018)

Genomic Profiling Reveals Differences in Primary Central Nervous System Lymphoma and Large B-Cell Lymphoma, With Subtyping Suggesting Sensitivity to BTK Inhibition
por: Severson, Eric A, et al.
Publicado: (2023)

Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma
por: Jagadeesh, Deepa, et al.
Publicado: (2022)

Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs
por: Matasar, Matthew J., et al.
Publicado: (2019)

Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden
por: Liang, Winnie S., et al.
Publicado: (2018)

Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy
por: Burke, John M, et al.
Publicado: (2023)

Humoral Immunity After COVID-19 Vaccination in Chronic Lymphocytic Leukemia and Other Indolent Lymphomas: A Single-Center Observational Study
por: Doukas, Peter G, et al.
Publicado: (2023)

Long-Term Risk of Subsequent Malignant Neoplasms Among Childhood and Adolescent Lymphoma Survivors (1975-2013): A Population-Based Predictive Nomogram
por: Liu, Junqi, et al.
Publicado: (2023)

Pegaspargase Combined with Concurrent Radiotherapy for Early‐Stage Extranodal Natural Killer/T‐Cell Lymphoma, Nasal Type: A Two‐Center Phase II Study
por: Wang, Hua, et al.
Publicado: (2020)

Renaissance of Radiotherapy in Intestinal Lymphoma? 10‐Year Efficacy and Tolerance in Multimodal Treatment of 134 Patients: Follow‐up of Two German Multicenter Consecutive Prospective Phase II Trials
por: Reinartz, Gabriele, et al.
Publicado: (2020)

Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim
por: Michel, Marc, et al.
Publicado: (2011)

High prevalence of cardiovascular and respiratory abnormalities in advanced, intensively treated (transplanted) myeloma: The case for ‘late effects’ screening and preventive strategies
por: Samuelson, Clare, et al.
Publicado: (2016)

C–C motif ligand 11 reduction in CLL patients serum after vitamin D supplementation
por: Kubeczko, Marcin, et al.
Publicado: (2016)

1q21 Gain Combined with High‐Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China
por: Li, Xiaozhe, et al.
Publicado: (2019)

Patient‐Reported Factors in Treatment Satisfaction in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
por: Chari, Ajai, et al.
Publicado: (2019)

More Insights on the Use of γ‐Secretase Inhibitors in Cancer Treatment
por: López‐Nieva, Pilar, et al.
Publicado: (2020)

Impact of a Multidisciplinary Tumor Board on the Care of Patients with Histiocytic Disorders: The Histiocytosis Working Group experience
por: Goyal, Gaurav, et al.
Publicado: (2022)

Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma
por: Jakubowiak, Andrzej J, et al.
Publicado: (2022)

Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease
por: Martini, Dylan J, et al.
Publicado: (2022)

PCM1-JAK2 Fusion Tyrosine Kinase Gene-Related Neoplasia: A Systematic Review of the Clinical Literature
por: Kaplan, Henry G, et al.
Publicado: (2022)

Physical Function, Psychosocial Status, and Symptom Burden Among Adults with Plasma Cell Disorders and Associations with Quality of Life
por: Jensen, Christopher E, et al.
Publicado: (2022)

A Systematic Review of Decision Aids in Hematologic Malignancies: What Are Currently Available and What Are We Missing?
por: Zhao, Janice, et al.
Publicado: (2022)

Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies
por: Muñoz, Javier, et al.
Publicado: (2023)

Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes
por: Mukherjee, Sudipto, et al.
Publicado: (2023)

Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma
por: Fonseca, Rafael, et al.
Publicado: (2023)

Successful treatment of diffuse large B-cell lymphoma with secondary hemophagocytic lymphohistiocytosis by R-CHOP-E regimen: a case report
por: Wu, Ran, et al.
Publicado: (2019)

Efficacy of ESHAP versus ICE plus dexamethasone (DICE) as salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
por: Boonlerd, Pattamaporn, et al.
Publicado: (2023)

Impact of C-reactive protein and albumin levels on short, medium, and long term mortality in patients with diffuse large B-cell lymphoma
por: Gradel, Kim Oren, et al.
Publicado: (2022)

Impact of HIV Infection on the Clinical Presentation and Survival of Non-Hodgkin Lymphoma: A Prospective Observational Study From Botswana
por: Milligan, Michael G., et al.
Publicado: (2018)

Lenalidomide maintenance for diffuse large B‐cell lymphoma patients responding to R‐CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study
por: Thieblemont, Catherine, et al.
Publicado: (2019)

Phase I study of novel SYK inhibitor TAK‐659 (mivavotinib) in combination with R‐CHOP for front‐line treatment of high‐risk diffuse large B‐cell lymphoma
por: Karmali, Reem, et al.
Publicado: (2022)

Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP
por: Procházka, Vít, et al.
Publicado: (2020)

Myelodysplastic syndrome with occult diffuse large B-cell lymphoma
por: Lee, Ja Young, et al.
Publicado: (2017)

Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R‐CHOP
por: Jeon, Young‐Woo, et al.
Publicado: (2019)

Leukemic Phase of CD5+ Diffuse Large B-Cell Lymphoma
por: Hsiao, Hui-Hua, et al.
Publicado: (2018)

Anaplastic diffuse large B-cell lymphoma: a deceptive morphology
por: Sivasubramaniam, Priyadharshini, et al.
Publicado: (2023)

The impact of SOCS1 mutations in diffuse large B‐cell lymphoma
por: Mellert, Kevin, et al.
Publicado: (2019)

The pretreatment albumin to globulin ratio predicts survival in patients with natural killer/T-cell lymphoma
por: Bi, Xi-wen, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_n97i9d8cpgdr73pjmrhags3379